Home › Funds › CAPITAL FUND MANAGEMENT S.A. › ALNY
CAPITAL FUND MANAGEMENT S.A. position in ALNY
ALNYLAM PHARMACEUTICALS INC · Health Care
CAPITAL FUND MANAGEMENT S.A. reported holding 155,904 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$46.9M, representing 0.62% of its reported portfolio and ranking #15 among its reported holdings. CAPITAL FUND MANAGEMENT S.A. has disclosed ALNY holdings in 5 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How CAPITAL FUND MANAGEMENT S.A.'s ALNY position evolved
CAPITAL FUND MANAGEMENT S.A. first disclosed a stake in ALNY in Q1 2024 at 30,367 shares (US$4.5M). The position peaked in Q2 2026 at 155,904 shares, worth US$46.9M. Across 5 filings, CAPITAL FUND MANAGEMENT S.A. increased the stake 3 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 155,904 shares valued at US$46.9M — an increase of 15,795 shares quarter over quarter.. Notable position changes include a 38% increase in Q2 2024 (shares rose 13% over the following quarter), a 569% increase in Q1 2026 (shares fell 8% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 30.37K | $4.54M | New |
| Q2 2024 | 41.82K | $10.16M | Add |
| Q4 2025 | 20.94K | $8.33M | New |
| Q1 2026 | 140.11K | $46.36M | Add |
| Q2 2026 | 155.90K | $46.93M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ALNY and 13F data
ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 36 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$734.5M), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALNY
- T. Rowe Price Investment Management, Inc. 5.64M sh · $1.70B · Q2 2026
- Baillie Gifford & Co 2.44M sh · $734.48M · Q2 2026
- Orbis Allan Gray Ltd 1.99M sh · $598.27M · Q2 2026
- Two Sigma Investments 1.88M sh · $564.71M · Q2 2026
- AMERICAN CENTURY COMPANIES INC 1.85M sh · $558.10M · Q2 2026
- TWO SIGMA ADVISERS, LP 1.13M sh · $450.36M · Q4 2025
- Deep Track Capital, LP 825.00K sh · $248.35M · Q2 2026
- Qube Research & Technologies Ltd 798.72K sh · $240.44M · Q2 2026
- LOS ANGELES CAPITAL MANAGEMENT LLC 729.63K sh · $219.64M · Q2 2026
- LOOMIS SAYLES & CO L P 580.19K sh · $174.65M · Q2 2026
More on CAPITAL FUND MANAGEMENT S.A.
FAQ
How long has CAPITAL FUND MANAGEMENT S.A. held ALNY?
CAPITAL FUND MANAGEMENT S.A. has disclosed ALNY holdings in 5 of the last 10 reported quarters, going back to Q1 2024.
What is CAPITAL FUND MANAGEMENT S.A.'s current position in ALNY?
As of Q2 2026, CAPITAL FUND MANAGEMENT S.A. holds 155.90K shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $46.93M, representing 0.62% of its reported portfolio and ranking #15.
Has CAPITAL FUND MANAGEMENT S.A. been buying or selling ALNY?
In the latest 13F filing (Q2 2026), CAPITAL FUND MANAGEMENT S.A. increased its position in ALNY. The position peaked in Q2 2026 at 155.90K shares.
Which other funds hold ALNY?
Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.